Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae
Jacqueline Findlay, Céline Rens, Laurent Poirel, et al.
Antimicrobial Agents and Chemotherapy (2022) Vol. 66, Iss. 10
Open Access | Times Cited: 14

Showing 14 citing articles:

ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
William R. Miller, César A. Arias
Nature Reviews Microbiology (2024) Vol. 22, Iss. 10, pp. 598-616
Closed Access | Times Cited: 138
Novel Antimicrobial Agents for Gram-Negative Pathogens
Marios Karvouniaris, Maria Panagiota Almyroudi, Mohd H. Abdul‐Aziz, et al.
Antibiotics (2023) Vol. 12, Iss. 4, pp. 761-761
Open Access | Times Cited: 21
Reviewing novel treatment options for carbapenem-resistant Enterobacterales
Natalie Mackow, David van Duin
Expert Review of Anti-infective Therapy (2024) Vol. 22, Iss. 1-3, pp. 71-85
Closed Access | Times Cited: 7
Evolution of Antimicrobial Resistance in Klebsiella pneumoniae over 3 Years (2019–2021) in a Tertiary Hospital in Bucharest, Romania
Alexandra Cireșă, Daniela Tălăpan, Carmen-Cristina Vasile, et al.
Antibiotics (2024) Vol. 13, Iss. 5, pp. 431-431
Open Access | Times Cited: 6
In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification
Eva Gato, Paula Guijarro-Sánchez, Isaac Alonso-García, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 4, pp. 106935-106935
Closed Access | Times Cited: 14
Comparison of the in vitro activities and resistance mechanisms against imipenem–relebactam and ceftazidime–avibactam in clinical KPC-producing Klebsiella pneumoniae isolated in China
Yingyi Guo, Likang Yao, Jiong Wang, et al.
Infection (2025)
Open Access
In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance
Shizuo Kayama, Sayoko Kawakami, Kohei Kondo, et al.
Journal of Global Antimicrobial Resistance (2024) Vol. 38, pp. 12-20
Open Access | Times Cited: 3
bla KPC-2 overexpression and bla GES-5 carriage as major imipenem/relebactam resistance mechanisms in Pseudomonas aeruginosa high-risk clones ST463 and ST235, respectively, in China
Yue Li, Fang Li, Mengqian Dong, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 11
Open Access | Times Cited: 7
In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series
Matteo Boattini, Gabriele Bianco, Sara Comini, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024)
Open Access | Times Cited: 2
Impact ofompk36genotype and KPC subtype on thein vitroactivity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producingK. pneumoniaeclinical isolates
Tara M Rogers, Ellen G Kline, M. Patrick Griffith, et al.
JAC-Antimicrobial Resistance (2023) Vol. 5, Iss. 2
Open Access | Times Cited: 5
Exploring avibactam and relebactam inhibition of Klebsiella pneumoniae carbapenemase D179N variant: role of the Ω loop-held deacylation water
T. A. Alsenani, S. L. Viviani, Krisztina M. Papp‐Wallace, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 10
Open Access | Times Cited: 4
Mutations in ompK36 differentially impact in vitro synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing Klebsiella pneumoniae
Tara M Rogers, Ellen G Kline, M. Patrick Griffith, et al.
JAC-Antimicrobial Resistance (2023) Vol. 5, Iss. 5
Open Access | Times Cited: 4
In vitro activity of newer β-lactam/β-lactamase inhibitor combinations, cefiderocol, plazomicin and comparators against carbapenemase-producing Klebsiella pneumoniae isolates
Sofia Maraki, Viktoria Eirini Mavromanolaki, Dimitra Stafylaki, et al.
Journal of Chemotherapy (2023) Vol. 35, Iss. 7, pp. 596-600
Closed Access | Times Cited: 3
Karbapenemaz Üreten Klebsiella pneumoniae İzolatlarında Seftazidim-Avibaktam, Meropenem-Vaborbaktam ve İmipenem-Relebaktam İnvitro Etkinliğinin Gözden Geçirilmesi
Özlem Aydemir, Mehmet Köroğlu, Elif ÖZÖZEN ŞAHİN, et al.
Mediterranean Journal of Infection Microbes and Antimicrobials (2023)
Open Access
Page 1

Scroll to top